HOME MONITORING PRODUCTS
Health authorities universally agree that effective tools to improve patient self-management of chronic diseases are critically important.
With superior ergonomics and best in class components, the second generation AirSonea is currently in development to complete our asthma management ecosystem; breath sensor, digital health platform and mobile app.
The app features asthma management diary features; medication usage and reminders, and symptoms and triggers to help asthma sufferers gain a better understanding of how their condition affects them and importantly, help them better adhere to their treatment plans. Further features including weather conditions and pollen count are planned.
Features first generation AirSonea, not available for sale. Gen II coming soon.
SonoSentry is the first over-the-counter wheeze detection device cleared by the FDA. It is a stand alone device with on board computation. Currently USB connected to PC, but data can be uploaded to cloud via web portal.
Symptoms of asthma, including wheeze, are generally worse at night and early morning. The FDA cleared Wholter is designed for 8-24 hour home ambulatory recording (nocturnal wheeze, cough). This option of monitoring asthma patients and collecting data for a period of time in the patient’s own home is important for both doctor in their design of treatment plans and patient, particularly parents of children with asthma. Respiri is currently exploring an upgrade to wireless capability and app function.
CLINICAL/HOSPITAL MONITORING (PULMOTRACK)
PulmoTrack™ Computerised Wheeze Detection
PulmoTrack is Respiri’s foundation product, designed for hospital/clinical based real-time monitoring of wheeze and cough in the management of acute, sever asthma in the ER and ICU, and for Pediatric Pulmonary Function Testing and Sleep Labs. The PulmoTrack module has a wireless connection to a PC. PulmoTrack is FDA cleared.